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This paper summarizes the deliberations of a work group charged with addressing specific questions
relevant to risk estimation in developmental neurotoxicology. We focused on eight questions.
a) Does it make sense to think about discrete windows of vulnerability in the development of the
nervous system? If it does, which time periods are of greatest importance? b) Are there cascades of
developmental disorders in the nervous system? For example, are there critical points that determine
the course of development that can lead to differences in vulnerabilities at later times? c) Can
information on critical windows suggest the most susceptible subgroups of children (i.e., age groups,
socioeconomic status, geographic areas, race, etc.)? d) What are the gaps in existing data for the
nervous system or end points of exposure to it? e) What are the best ways to examine
exposure-response relationships and estimate exposures in vulnerable life stages? f) What other
exposures that affect development at certain ages may interact with exposures of concern? g) How
well do laboratory animal data predict human response? h) How can all of this information be used to
improve risk assessment and public health (risk management)? In addressing these questions, we
provide a brief overview of brain development from conception through adolescence and emphasize
vulnerability to toxic insult throughout this period. Methodological issues focus on major variables
that influence exposure or its detection through disruptions of behavior, neuroanatomy, or
neurochemical end points. Supportive evidence from studies of major neurotoxicants is provided.
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To address critical windows of exposure that
impact neurological function, it is important
to recognize the importance of multiple fac-
tors. It is necessary to understand that these
windows of exposure are influenced by the
mechanism of action of the agent, the target
tissue dose of the agent, the developmental
time table of the target tissue, the end point
(outcome) of interest, and the age and man-
ner in which that outcome is evaluated
[Wilson (1) provides an introduction to
these now well-established principles].
Different functions are mediated by different
neural substrates, and the timing of develop-
mental events varies with neural substrate.
Thus, vulnerability associated with specific
time periods of exposure varies with the
agent of exposure and the end point of inter-
est. It is also important to recognize the pro-
tracted period of development of the nervous
system. The architecture and physiology of
the brain develop throughout gestation and
continue postnatally through adolescent
development. Insult at any point during this
period may result in aberrant neural structure
or function.
Specific aberrant outcomes have been
associated with particular windows of vulner-
ability to specific agents: these developmental
windows begin before the formation of the
neural plate and end with pubertal neuromat-
uration. Most neurally active agents appear
able to disrupt development at multiple time
points across this broad protracted period.
Depending on the timing of exposure, the
end points affected may also vary. For a single
end point, however, there is often a period of
greatest vulnerability as defined by the pro-
duction of the outcome at a lower level of
exposure to the agent. The outcome itself
may be expressed only after (or perhaps at) a
particular developmental stage and may be
revealed only under certain conditions of
measurement. Natural conditions such as
aging or experimental conditions such as
social, pharmacological, or other environ-
mental challenges may be necessary to reveal
the deficit.
Inherent in the brain's protracted period
of development, however, is also the phe-
nomenon of neuroplasticity and the nervous
system's consequent potential for compensation
after insult. Although it is important to
understand the role that compensatory mecha-
nisms may play in the manifestation of the
effects of developmental exposures, our view is
that the detection of adverse outcomes at any
age is a primary goal of screening and risk
assessment, and transient as well as permanent
adverse effects need to be guarded against. For
this reason, we view an examination of neuro-
plasticity as beyond the scope of this review.
The protracted period of development
and the protracted period over which out-
comes must be measured to adequately assess
dysfunction of the nervous system compli-
cate the establishment of causal relationships
in epidemiological studies of developmental
toxicity. Certain aberrations in development
are directly caused by exposure-based events
(e.g., abnormalities in the development of
the hypothalamic-pituitary axis), whereas
others may represent downstream conse-
quences of exposure (e.g., reduced body
weight, increased vulnerability to birth
trauma, altered responses to stress, and
decrements in learning and memory). It is
important to distinguish between primary
developmental aberrations caused by toxic
exposure and downstream effects. It is also
important to recognize that although there
are numerous outcomes of developmental
neurotoxicity, their expression (and measure-
ment) is limited to a finite set of readily
observable outcomes. Such abnormalities
may include specific aberrations resulting
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from diverse events, potentially emerging at
different times. Just as different mechanisms
may lead to grossly similar anatomical
expression (e.g., gross examination may not
distinguish missing tissue due to agenesis vs.
overactive apoptosis), different mechanisms
and primary neural abnormalities may lead
to similar behavioral manifestations (e.g.,
neurochemical dysfunction due to altered
neurotransmitter production or to altered
receptor dynamics may similarly alter behav-
ior). Functional alterations serve as apical
tests of underlying primary neuroanatomical,
neurophysiological, and/or neurochemical
abnormalities resulting from exposure.
The ease of detecting the primary under-
lying abnormalities varies with the resolution
of the technology. As a result, behavioral dis-
ruptions may sometimes be detected in ani-
mals or in children whose neuropathology
remains unidentified by standard means. The
failure to consistently identify neuroanatomi-
cal abnormalities in animals with behavioral
dysfunction has led to some investigators'
conceptualizations of robust behavioral
effects subtle. Although the extent to which
such effects may defy detection has merited
their being labeled subtle, the term should
not be used to imply milder. Ambiguity is
often present in the interpretation of certain
so-called subtle behavioral effects as poten-
tially mild when seen in rodents; the ambigu-
ity is easily resolved in human manifestations.
For example, identification of gross neu-
ropathology has not been consistently possi-
ble in studies of mentally retarded children
(2); however, mental retardation would not
be considered a mild effect when produced
by a toxic exposure. Unfortunately, however,
the connotation of the "subtle" terminology
has, in part, led some to misinterpret the
model of severity of outcome, where frank
malformation is at one end of a continuum
and behavioral dysfunction at the other. This
has sometimes led to the incorrect conceptu-
alization of detectable anatomical changes in
any organ system as being more severe out-
comes of exposure than behavioral impair-
ments, when dysfunction was not
accompanied by gross pathology of the brain.
For many compounds (ethanol, retinoic
acids, and valproic acid), the nature of the
dose-response relationships suggests that
higher doses are associated with outcomes such
as major malformations, whereas lower doses
produce behavioral change in the absence of
grossly detectable neuropathology. However,
many (perhaps most) environmental develop-
mental toxicants that influence behavioral,
hormonal, or growth outcomes do so in the
absence of malformation induction at higher
doses where maternal toxicity and/or fetal
death may occur [e.g., lead, mercury, poly-
chlorinated biphenyls (PCBs), amphetamine,
and cocaine]. Thus, in the context of screen-
ing, behavioral alteration may sometimes be
the only marker for risk assessment. Research
has clearly linked behavioral dysfunction with
ultrastructural or molecular abnormalities in
brain development; however, these end points
are not part of current screening approaches.
In this paper, we interweave empirical
evidence for our opening perspective with
our responses to the eight specific questions
provided as workshop directives. 1) Does it
make sense to think about discrete windows
of vulnerability in the development of the
nervous system? If it does, which time peri-
ods are of greatest importance? 2) Are there
cascades of developmental disorders in the
nervous system? For example, are there criti-
cal points that determine the course of devel-
opment, which can lead to differences in
vulnerabilities at later times? 3) Can informa-
tion on critical windows suggest the most
susceptible subgroups of children (i.e., age
groups, socioeconomic status, geographic
areas, race, etc.)? 4) What are the gaps in
existing data for the nervous system or end
points of exposure to it? 5) What are the best
ways to examine exposure-response relation-
ships and estimate exposures in vulnerable
life stages? 6) What other exposures that
affect development at certain ages may inter-
act with exposures of concern? 7) How well
do laboratory animal data predict human
response? 8) How can all of this information
be used to improve risk assessment and




The first question considered at the work-
shop was as follows: Does it make sense to
think about discrete windows of vulnerabil-
ity in the development of the nervous sys-
tem? If it does, which time periods are of
greatest importance? Empirical evidence
substantiates multiple periods of vulnerabil-
ity to toxic insult in the developing nervous
system spanning from early gestation to ado-
lescence in humans and experimental animal
models (3-5). Toxic insults during this pro-
tracted period can result in diverse outcomes
ranging from structural abnormalities emer-
gent during early embryogenesis that may be
incompatible with pre- or postnatal survival,
to ultrastructural or molecular abnormalities
potentially emergent at any developmental
point and associated with functional deficits.
Wilson (1) originally described the manifes-
tations of abnormal development as repre-
sented by four main categories: death,
malformation, growth retardation, and func-
tional deficit. He also put forth as a princi-
ple of teratology that "manifestations of
deviant development increase in frequency
and degree as dosage increases from the
no-effect to the totally lethal level." Some
developmental toxicants that are capable of
disruption of morphogenesis through molec-
ular mechanisms demonstrate this conven-
tional neuroteratogenic profile whereby all
outcomes on the continuum of abnormal
development may be induced at different
stages and varying exposures [e.g., retinoids
(6,7)]. However, other developmental toxi-
cants that act through the disruption of
other morphogenetic signaling or neuro-
transmitter systems appear not to produce
gross malformations at doses below those
capable of producing maternal toxicity.
These agents produce robust effects that are
less readily detectable and less easily associ-
ated with narrow periods of heightened vul-
nerability than is the case when gross
malformations are produced. Nevertheless,
the consequences may be equally robust.
Thus, multiple neuroanatomical, molecular,
and behavioral end points are necessary to
assess the effects of insult to the developing
nervous system. The windows of greatest
vulnerability to disruption of the neural
mediators of these various outcomes vary
with the agent of exposure, dose of the
agent, and its associated mechanism of
action, as well as the age at assessment and
other characteristics of the assessment
methodology. Thus, it makes sense to think
about discrete windows of vulnerability only
when we recognize the importance of other
variables. Empirical evidence demonstrates
that exposure during finite windows of
exposure produces quantitatively and quali-
tatively different outcomes. This has been
demonstrated not only in relation to multi-
ple outcomes of prenatal exposure but also
after exposure during different windows of
postnatal development in rodents [e.g.,
organotins (8-10)]. Thus, it makes sense to
think about windows of vulnerability only in
the context of a specific end point or set of
end points; otherwise, defining the most vul-
nerable period requires that outcomes be
evaluated according to a severity index. In
the case of hazard identification for chemi-
cals in which limited data exist on mecha-
nism or mode of action or little information
is available in the literature examining criti-
cal windows of exposure and developmental
effects, it becomes hard to assume what the
critical window of exposure may be. In these
cases the default assumption could be that
the entire period of neural development may
be vulnerable (i.e., beginning before neuru-
lation and ending after puberty). We first
consider the range of end points necessary to
assess potential developmental effects of tox-
icity. We then address the windows of great-
est vulnerability for effects on selected
outcomes. Finally, we discuss assessment
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characteristics that appear relevant to the
detection of toxic insults.
Necessity of Multiple End Points
to Detect Potential Developmental
Neurotoxicity
Because developmental neurotoxicity can be
expressed through anatomical, physiologi-
cal, neurochemical and/or behavioral end
points, assessments of multiple end points
are necessary. Because there are a multitude
of measures for the study of structural or
functional effects of exposure, it is most
efficient to focus on more mainstream mea-
sures incorporated into screening studies
[reviewed by Meyer (11), Kimmel (12),
Adams (13), and the U.S. Environmental
Protection Agency (EPA) (14)]. We com-
pare screening methods with techniques
that have emerged as the most valuable
from a range of scientific studies conducted
in the last decade. Studies in developmental
toxicology may examine anatomical and
gross physical end points along with behav-
ioral ones. Although behavioral measures
themselves have been limited in testing bat-
teries, they have nevertheless often been
more extensive than corresponding exami-
nations of neuroanatomical or neurochemi-
cal end points. In the context of screening
studies conducted in rodents, the need for a
battery of tests to measure functioning in
diverse behavioral systems has long been
recognized (15,16). The development of
behavioral testing batteries has received more
regulatory attention than has the need for a
sophisticated battery approach that includes
the examination of current neuroanatomical
or neurochemical/molecular end points.
More extensive measurement of neural struc-
tures and neurochemical systems must be
incorporated with a more sensitive modern-
day behavioral screening battery. The inclu-
sion of neurochemical assessments during
critical periods of maturation and in adults
with prior developmental exposure may be
warranted in cases where chemicals affect
specific neurotransmitter systems in either in
vitro assays or in the adult nervous system
after exposure. This is predicated on the
qualitatively different role as neurotrophic
factors that neurotransmitter systems play
during development [reviewed by Buznikov
et al. (17) and Rice and Barone (18)].
Behavioral test batteries generally contain
measures of viability, growth, and physical
developmental landmarks along with mea-
sures of motor development, sensory func-
tioning, activity levels, reactivity, and
learning and memory. The rationale for this
screening battery approach emphasizes that
different agents and exposures at different
times to the same agents result in effects on
different systems measured within the battery
(19,20). Because most regulatory approaches
to screening have incorporated relatively long
exposure windows, assessing a multitude of
potentially vulnerable systems is paramount.
In the context of windows of vulnerability,
we must always recognize that the window of
greatest vulnerability may vary with the end
point under examination. If the relevant
end point is not examined, the effects will
not be detected. Likewise, if the relevant end
point is inadequately assessed, effects may
not be evident.
Use of the battery approach in the last
decade has reinforced the need to assess the
categories of functioning but has challenged
the value of or suggested more valuable mea-
sures within each category. Also, routine
incorporation of other methods in research
studies has demonstrated the value of examin-
ing other end points.
Distinctive Neural Systems Have
Different Periods ofVulnerability
Different areas of the brain mediate different
types of information processing and are
related to different kinds of neural function.
Whereas all neural processing involves multi-
ple neural centers and major pathways con-
necting specific structures, it is heuristic to
recognize certain critical sites. Rice and
Barone (18) discuss the following areas in
their background paper: prefrontal structures
for working memory and executive func-
tions; medial temporal lobe structures for
certain aspects of learning and memory; and
brainstem structures for regulation of
arousal, sleep-wake cycles, and multiple
autonomic nervous system functions. Each
area has its own protracted period during
which neurogenesis, migration, specification,
elaboration of neurons, apoptosis, and inter-
nal synaptic connectivity as well as establish-
ment of input/output circuits take place. The
background paper by Rice and Barone (18)
and a review by Holson (21) provide infor-
mation on specific time periods for different
brain areas. Jensen and Catalano (22) pro-
vide an overview of nervous system morpho-
genesis; their overview is a primary source for
this limited extraction. In light of brain area
and circuit-dependent differences in the tim-
ing of developmental events, it is not surpris-
ing that behaviors mediated by different
brain systems would be disrupted by insults
at different times during development. It is
also not surprising that disruption of some
embryonic developmental events results in
gross malformations as a consequence,
whereas more commonly, developmental
insults result in cytoarchitectural or molecu-
lar alterations. Therefore, the particular agent
and end point under investigation will deter-
mine the temporal window identified as
most vulnerable to insult.
Neural Vulnerability Spans from Early
in Gestation through Adolescence
A series of developmental events appear to
define periods of greatest vulnerability to
insult. These developmental events occur at
different times for different neural struc-
tures and circuits. Thus, there is no simple
categorization of morphogenesis of the cen-
tral nervous system into discrete temporal
nonoverlapping categories. Therefore, our
discussion of vulnerable windows is kept very
broad, instead emphasizing the protracted,
interactive, and temporally overlapping
nature of stages and major morphogenetic
events. Our discussion incorporates the
embryonic, fetal, and early postnatal periods
of brain development, then focuses on ado-
lescent brain development. We provide sup-
portive evidence for disruption of different
processes and events for selected agents.
Vulnerability before induction of the
neural plate through neural tube closure
andformation of the rhombencephalon.
The period in human pregnancy that occurs
before the induction of the neural plate is
before day 18 postconception. In the rat, this
period is before day 9. Toxic disruption of
developmental events prior to neural induc-
tion has been demonstrated after early expo-
sures to diabetic conditions, retinoic acid,
methylnitrosourea, and clomiphene [reviewed
by Bennett and Finnell (23)]. Such exposures
resulted in an increased incidence of neural
tube defects and certain other malformations
despite exposure before neurulation.
Better understood, however, are the
effects of toxic agents during the neurulation
process itself (human: approximately days
18-28, rat: approximately days 9-12) primar-
ily in regard to insults that result in death or
neural tube defects qualifying as major mal-
formations (6,22,23). Such malformations
include anencephaly, spina bifida, encephalo-
celes, and myelomeningoceles. Classic terato-
gens include retinoic acid, arsenic, and
valproic acid as well as hyperthermia [retinoic
acid was reviewed by Adams (6) and Adams
and Holson (7); other agents were reviewed
by Bennett and Finnell (23)]. These agents
appear to evoke diverse mechanisms that
result in neural tube defects as a final com-
mon, categorically similar outcome.
Abnormalities other than the classic mal-
formations can also result from exposures
before and around neural tube closure,
around the time of rhombomere formation
(23,24). Effects on hindbrain structures such
as brainstem and cranial nerve nuclei are
clearly demonstrated by exposures to valproic
acid and thalidomide (24,25). Effects on
brainstem, cranial nerve nuclei, and cerebellar
structures have also been shown after expo-
sures to retinoic acids (7,26-29). Early on,
these agents were associated with behavioral
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deficits in the absence of identified
neuropathology [retinoic acid was reviewed
by Adams (6) and Adams and Holson (7);
valproic acid was reviewed by Dansky and
Finnell (30), Finnell and Dansky (31), and
Hansen and Holson (32)].
Brain development after neural tube
closure: vulnerability in multiple processes
and events that are interactive and over-
lapping. Morphogenesis of the nervous
system begins with the induction of the
neural plate and continues into postnatal
development. Although neurogenesis was
originally believed to end during the early
postnatal years in humans, it is now recog-
nized to be present to a limited degree
throughout life [reviewed by Kempermann
and Gage (33)]. Nevertheless, extensive neu-
rogenesis is limited to early development in
humans, and in rats appears to encompass
gestational days 11-22, except the hippocam-
pal and cerebellar microneurons, which
develop postnatally in the rat (21). During
early stages, the segmented brain first devel-
ops into a trivesicular organ that includes the
rhombencephalon, mesencephalon, and pros-
encephalon. The migration of neurons even-
tually results in the formation of all structures
of the brain. During this extended period of
morphogenesis, multiple processes occur that
are necessary for the development of neuronal
and glial elements and their complex cir-
cuitry. Intra- and intercellular interactions
involving multiple trophic agents constantly
act to create, shape, and then remodel the
brain and nervous system. Clearly, descrip-
tions of these developmental events are
beyond the scope of this paper. A detailed
overview of the processes and events of brain
development can be found in Jensen and
Catalano (22). Rice and Barone (18) discuss a
temporal characterization of processes such as
proliferation, migration, synaptogenesis, glio-
genesis and myelinogenesis, and apoptosis in
relation to particular brain areas. Barone (34)
and Barone et al. (35) provide more extensive
reviews of processes, signaling, and trophic
molecules involved in development. Of
importance here is the fact that toxic interfer-
ence with these fundamental developmental
processes and multiple signaling and trophic
agents has been well documented to result
not just in malformations, but more com-
monly in cytoarchitectural and molecular
alterations that are expressed as behavioral
dysfunction. For environmental agents associ-
ated with long-term exposure patterns, behav-
ioral, neuronal, or molecular effects have been
associated with a greater number of agents
than have the early developmental malforma-
tions associated with classic teratogens. Thus,
environmentally relevant levels of lead, mer-
cury, pesticides, PCBs, and many other
agents pose a greater threat to perturbation of
developmental processes like synaptogenesis
than to expressions of insult through gross
malformations. Herein lies the dilemma:
qualitative histological examination of Nissl-
stained sections of the brain (as required by
some guidelines) does not adequately assess
neuroanatomical and neurochemical charac-
teristics with the resolution necessary to
detect these changes. Morphometric analysis,
at least on a regional level during brain devel-
opment, can provide some estimates of delays
in synaptogenesis or persistent alterations in
synaptogenesis and/or dendritic elaboration
[reviewed by Barone et al. (35)]. Likewise,
some methods of evaluating alterations in
behavior or other neurological functions may
be inadequate to detect many subtle effects.
This could be critical for child health protec-
tion if subtle effects in animals are missed or
in some instances dismissed because they are
only observed in the highest dose group under
study and are possibly confounded with
indices of maternal toxicity. Let us consider
lead and methyl mercury toxicity to illustrate
the relationship among neuroanatomical, neu-
rochemical, and behavioral effects. These
agents were selected because of their historical
prominence, their relevance to regulatory
actions, and the extent of available data. They
allow discussion not only of outcomes but also
of primary substrates that are affected, and also
illustrate some age-dependent vulnerabilities.
Broader discussion can be found in Rice and
Barone (18), Dietrich (36), and Bellinger and
Dietrich (37).
Lead. Lead is a good example of a devel-
opmental toxicant whereby under condi-
tions of long-term, low-level exposure,
behavioral disruption is the primary out-
come. Bellinger and Dietrich (37), Dietrich
et al. (38), and Rice (39,40) published excel-
lent reviews on this subject. Exposures that
are mostly postnatal and often restricted to
infancy (substantiated in these reviews) as
well as prenatal exposures (41) have been
associated with the production of general
intellectual deficits as well as deficits in spe-
cific sensory and cognitive abilities. The
fetuses and children appear more susceptible
to these effects than adults. Effects on gross
brain structure have not been evident in
studies directed at understanding underlying
neuropathology associated with low-level
lead exposure. Instead, the effects most con-
sistently noted are those on synaptogenesis
and dendritic arborization (42-46), in vivo
physiological examinations of synaptic plas-
ticity (47-49), and decrements in myelina-
tion (50,51). Changes in glutamate and
y-aminobutyric acid synthesis and release
(52,53) and the glutamate N-methyl-D-
aspartate (NMDA) receptor levels and bind-
ing affinities have also been reported in
association with low-level lead exposure
(54). Direct inhibitory actions of lead on
NMDA receptors in the hippocampus have
also been associated with and used to explain
synaptic changes as well as cognitive impair-
ments in lead-exposed rodents and children
(54). Thus, lead exposure can disrupt devel-
opmental events that begin prenatally but
continue during early childhood, and can do
so at multiple points during that interval.
Methyl mercury. Because of the poison-
ing at Minamata Bay, Japan, in the mid-
1950s, the results of high- as well as lower
level exposures to methyl mercury have
received a great deal of research attention. As
was the case for lead, the fetus and child are
more susceptible to methyl mercury toxicity
than adults [reviewed by Chang et al. (55)
and Burbacher et al. (56)]. Burbacher et al.
(56) examined the comparative characteristics
of methyl mercury exposure to developing
humans, macaque monkeys, and rodents.
They showed clear dose-response effects for
behavioral as well as neuropathological end
points that were quite consistent across
species. Effects were examined across low (< 3
ppm), moderate (3-11 ppm), and high
(12-20 ppm) doses defined by brain tissue
content. Dose-related effects on behavioral
outcomes were manifested as cognitive
deficits or delayed development at low doses,
cognitive and sensory electrophysiological
effects at moderate doses, and severe sensory
(blindness), cognitive, and motor (spasticity)
abnormalities as well as seizures at high doses.
Neuropathological effects in rodents exposed
across these dose ranges included cellular loss
and decreased brain size at low doses,
decreased brain size, cortical and cerebellar
defects, and reduced myelin at moderate
doses, and these same effects plus effects on
additional brain structures at high doses.
More recent work has identified disruptions
in neuronal proliferation and migration, dys-
myelination, hypoplasia of the corpus callo-
sum, and hydrocephalus in association with
high doses; lower level exposures have been
associated with migration and cytoarchitec-
tural defects (57). Mediation of toxic effects
on neural development may involve alter-
ations in cell adhesion molecules and
cytoskeletal proteins (56) and neurotrophic
factor signaling (58-60).
Vulnerability during the adolescent
period ofdevelopment. In addition to the
dramatic neuroendocrine and physical
changes associated with adolescence, from
even the limited amount of literature avail-
able, it is clear that the brain of the adoles-
cent also undergoes striking transformations.
Several brain regions undergo prominent
remodeling during adolescence across a vari-
ety of species. These regions include the pre-
frontal cortex and other forebrain regions to
which mesolimbic dopaminergic terminals
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project. In addition to an adolescent-
associated decline in the volume of the pre-
frontal cortex [humans (61); rats (62)], there
is also substantial synapse elimination of pre-
sumed glutaminergic excitatory input in
motor cortex (63) while dopaminergic input
to the prefrontal cortex increases during ado-
lescence to reach levels higher than that seen
earlier or later in life [reviewed by Lewis
(64)]. Estimates of basal synthesis and
turnover of dopamine decline in prefrontal
cortex during adolescence in rats, which con-
trasts with the increase in these measures
reported in the nucleus accumbens and stri-
atal dopamine terminal regions of adolescent
rats (65,66). Maturational events have also
been reported in a variety of other areas
including the hippocampus [humans, (67);
rodents, (68), and hypothalamus (69)].
These data suggest that the adolescent
period of brain development should be a time
of particular vulnerability to insult. However,
there has been surprisingly little investigation
in either humans or animals of the vulnerabil-
ity of adolescent brain to developmental per-
turbation. Some studies in experimental
animals have begun to address this data gap.
Salimov et al. (70) reported that ethanol con-
sumption by adolescent alcohol-preferring
rats altered later behavioral responsiveness to
novelty and a swim stressor. Goliszek et al.
(71) reported that long-term stress of rats
from 4 to 10 weeks of age [a period that the
authors defined as prepubertal but which
should span the entire pubertal period
(72,73)] permanently altered the animal's
ability to release adrenocorticotropic hor-
mone, even when subjected to considerable
stress; males were particularly vulnerable in
this regard. These few examples clearly
demonstrate that explorations of the conse-
quences of insults during adolescent brain
development remain unexplored territory that
should be quite fertile for future research.
The detection of the effects ofdevelop-
mental toxicity can be optimized by atten-
tion to specific assessment characteristics.
Studies in developmental toxicity have
shown not only a protracted period of vul-
nerability but also a protracted period over
which the consequences are expressed.
Whereas one can simply say, for example,
that the behavior or neural system must first
have developed before its integrity of func-
tion can be examined, the issue is far more
complex. Among issues of importance are a)
neural mediators for particular behaviors
sometimes change with age, experience, or
the need for compensation; b) vulnerability
may vary with the sex of the individual; and
c) effects may only be detectable under more
challenging conditions. Data illustrating
these issues can be found in the background
paper by Rice and Barone (18).
These issues have been recognized for years
and now cumulative evidence demands
increased attention to the age of assessment.
The research issue to be resolved is whether
testing in screening studies of young adult
experimental animals alone is adequate to iden-
tify long-term consequences of developmental
perturbations. We focus only on the issue of
improved detectability under challenging con-
ditions. There are five approaches that could
reveal the subclinical long-term effects of
developmental exposure, whereby detectability
is revealed through a) aging-related functional
or morphological loss, b) pharmacological
challenge to the integrity of a particular neu-
rochemical system, c) response to environ-
mental stressors, d) increased task
complexity, or e) histological examination of
the brain that includes quantitative assess-
ments at different life stages. Long-term con-
sequences of chemical exposure during
development could be examined in an
adjunct way in screening studies evaluating
exposure over the lifetime in multigenera-
tion-reproductive screening studies.
Methyl mercury was the first compound
to draw considerable attention to the phe-
nomenon of developmental exposures mani-
festing effects revealed with aging (18,74,75).
Animal and human studies have identified
motor and sensory deficits with increasing age
that were not seen at earlier time points after
the cessation of exposure as well as a worsen-
ing of conditions with age. By way of compar-
ison to another agent, rats exposed to
triethyltin during early postnatal development
demonstrated decrements in cognitive perfor-
mance at 24 months of age that were not seen
at 3 months of age and at 1 year of age (76).
Pharmacological challenges have been
widely used in animal studies to examine
functioning in specific neurochemical systems
[reviewed by Meyer (11)]. Such challenges
serve as probes to evaluate the integrity of
particular systems that are pharmacological
targets of the developmental toxicant under
study or that influence behaviors under study.
Generally, agonists, antagonists, or agents
that up-regulate or down-regulate the trans-
mitter system are used. Historically, drug
challenge studies have been commonly used
to examine changes in activity, body tempera-
ture, tremor, forepaw treading, head weaving,
or threshold for catalepsy. These studies by
inference reflect changes in neural connectiv-
ity and neurotransmission.
Increased sensitivity to various environ-
mental stressors has also been seen in animals
exposed to developmental toxicants. For
example, the review by Spear et al. (77)
showed that rats prenatally exposed to
cocaine have increased sensitivity to stressors
such as early manipulation, social competi-
tion, and immobilization.
Animal models of multiple human mental
retardation disorders have demonstrated the
difficulty of most assessments of learning in
rats in capturing expected deficits, in part
because of the simplicity of routinely used
measures of learning and memory in rodents.
Task complexity unmasks various learning
deficits (78,79). Cumulative learning tasks
that require transfer of training experience
appear particularly useful in revealing learn-
ing deficits. This has been demonstrated in
multiple studies using operant schedules of
increasing complexity to examine deficits in
animals [reviewed by Rice and Barone (18)
and Paule et al. (80)]. Examinations of the
ability to shift or reverse learning rules pro-
vide added detection sensitivity in nonoper-
ant tasks such as versions of the water maze
and other tasks (19,81). Finally, learning
methods that make demands on working
memory, such as delayed alternation tasks
[reviewed by Rice and Barone (18)] or other
tasks that require timing or inhibition of
responses [reviewed by Paule et al. (80)],
appear to offer increased sensitivity. These
types of functional assessments can be more
sensitive to perturbation of the development
of the nervous system than tasks that use only
simple acquisition of spatial learning or one-




Ar There Critical Points That
Determine the Course ofDevelopment
That Can Lead to Differences in
Vulnerabilities at Liter Tunes?
We have emphasized a sequence of develop-
mental events that are interrelated, and we
also emphasized that functional effects
unfold throughout the lifespan. Certain
effects become evident only as relevant func-
tional capacities emerge. Other effects mani-
fest with declines in reserve capacities that
become functionally expressed subsequent to
aging or under more challenging test condi-
tions. Because the brain and behavior are
constantly influenced by experience, any
alteration in the integrity of nervous system
function at one point in time predisposes a
risk to the ongoing and future integrity of
the structure and function of the nervous sys-
tem. In this sense, cascades of effects are an
unavoidable consequence of the prime direc-
tive of nervous system functioning: the con-
tinual adaptation to environmental change
through constant processing of information
and neural remodeling.
Because of the cascade of effects that
exposure can have on development and func-
tion of the nervous system, sometimes there is
debate regarding which behavioral effects are
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primary and which may be secondary
consequences or downstream manifestations.
For example, we may wish to determine if all
children with comparably reduced intelli-
gence have correspondingly reduced attention
spans, or if a particular genetic disorder, dis-
ease, or agent appears to more selectively tar-
get neural substrates for attention. In a
risk-assessment environment, all detrimental
effects collectively represent effects to be
avoided. When cause-effect relationships
need to be scientifically understood for several
different behavioral outcomes, however, or
when intervention may be used to mitigate a
known cascade, it is useful to be able to tease
primary and secondary effects apart. Primary
effects are manifest on neural architecture or
physiology but may be expressed most
notably on altered behavioral functioning.
Certain behaviors are more proximal to the
neural effect caused by exposure than others.
For example, certain agents appear to alter
attention span, impulsivity, or activity levels
in children. As a subpopulation, children with
poor impulse control (for whom most etiolo-
gies are unknown) are at increased risk for
poor academic performance and accidents, for
the development of substance abuse disorders,
and even for criminal activity [reviewed by
Pennington (82)]. These downstream out-
comes have high societal costs and may occur
with increased risks in children exposed to a
variety of developmental toxicants (18).
Knowledge of the relationship between the
antecedent problems in impulse control and
the increased risk for later manifestation of
other sociobehavioral problems can be helpful
in channeling children and their families into
intervention programs to try to reduce future
correlated manifestations. It is difficult to fully
parse the effects of toxic exposure on child-
hood impulsivity versus increased criminality
because nonexposure-related variables might
intervene to determine the progression from
impulsivity to criminality. If we wish to asso-
ciate the effects of a developmental toxicant
with a downstream manifestation of this type,
we must design studies that attempt to further
address the intervening variables of impor-
tance (educational characteristics and family
and home characteristics). Research must not
only compare exposed children to demo-
graphically matched nonexposed children but
should also contrast the long-term behavioral
characteristics of exposed children with those
of children with similar early behavioral
characteristics (like impulsivity) not due to
exposure. This would allow determining
agent-specific versus more generic behavioral
profiles present in all children with predispos-
ing personal and familial risk factors.
In addition to the interrelated events that
determine each stage of nervous system devel-
opment and the functional cascades described
above, it is important to recognize that
developmental exposure to certain agents may
also alter later physiological or neurochemical
responses. For example, prenatal exposure to
cocaine (66,83,84) alters later pharmacologi-
cal sensitivity to dopaminergic agents as well





Neurobehavioral characteristics of children
are influenced by parental socioeconomic sta-
tus, parental age, educational background,
and ethnicity. These important variables
must be controlled through experimental
design or statistical procedures whenever
neurobehavioral outcomes are examined.
Further, infant characteristics such as sex,
small-for-gestational-age status at birth, and
the presence of birth complications increase
the risk for compromised motor or intellec-
tual development. This presents a dilemma
for associating early exposures with adverse
neurobehavioral effects, particularly when
the exposure reduces birth weight, increases
prematurity, and/or complicates the birth
process in other ways. At the screening level,
we deem it fully acceptable for the entire cas-
cade of events to be viewed as increased
because of exposure and therefore believe
that it represents effects that we would wish
to avoid for any environmental agent.
However, it may also be important to deter-
mine if the full cascade of effects is proto-
typical in incidence and generic to any child
born with comparably reduced birth weight,
comparable prematurity, or a comparable
experience of another birth complication.
This determination can be answered only
through studies with appropriate contrast
groups as well as control groups.
Gaps in Existing Data
Previous discussion has emphasized the need
for a) screening-level assessment of cytoarchi-
tectural aspects of neuroanatomy and molec-
ular aspects of function, b) expanded
knowledge of preembryonic exposure effects,
nonmalformation outcomes after embryonic
exposure, as well as effects consequent to
exposures during adolescence, and c) develop-
ment, validation, and incorporation of more
sensitive methods to assess learning and
memory within a screening context.
The issue of hazard characterization of
anatomical effects after developmental expo-
sure continues to be a problem of where and
when to look for alterations. Histological
examination using both qualitative and quan-
titative examination during development and
into adulthood can reveal adverse effects after
developmental exposure during different
critical periods (58,76,86). Currently, screen-
ing approaches, including examination of
representative structures of the brain that
develop both prenatally and postnatally, are
required under the U.S. EPA testing guide-
lines for developmental neurotoxicity (14).
This guideline was designed in the late 1980s
with apical measures in mind. As more data
become available using this guideline and
newer methods are developed, this guideline
for screening chemicals for developmental
neurotoxicity could and should evolve. A
number of practical considerations and scien-
tific issues will probably influence the devel-
opment of newer testing strategies. First, as
an example of the practical issues, there are a
large number of high production/volume
chemicals (approximately 3,000) that have
not been examined at all for developmental
neurotoxicity (87,88). This issue, among oth-
ers, suggests that alternative means of testing
and/or prioritization of testing may need to
be used. The Endocrine Disruptor Screening
and Testing Advisory Committee is an exam-
ple of this approach based on the develop-
ment and evaluation of a battery of in vitro
and in vivo tests with a scientifically sound
mechanistic basis. Currently, a number of in
vitro tests are available for testing different
processes critical to development of the ner-
vous system such as proliferation, differentia-
tion, and apoptosis; however, little
coordination of resources has been devoted to
the validation and application of such tests as
adjuncts to a developmental neurotoxicity
screening battery for testing chemical hazards.
In addition to hazard identification and pre-
liminary screening, these tests could serve to
provide some mechanistic underpinning for
how a chemical or class of chemicals affects
development of the nervous system. Develop-
mental neuroscience has provided a rapid
expansion of information about the genetic
and epigenetic control of developmental
processes. The use of both in vitro culture
models derived from rodents and human
stem cells and immortalized neurons derived
from humans may facilitate comparisons of
chemicals on the basis of effects on develop-
mental processes critical to normal vertebrate
brain development. Identifying the effects
related to aggregate and cumulative exposures
during development of the nervous system is
complex; however, future research could
examine these developmental processes both
in vitro and in vivo with the goal of identify-
ing the chemical's mode of action in a way
that could be extrapolated across species.
Additionally, consideration of the chronic
versus acute nature of potential human expo-
sures and of relevant pharmacokinetic infor-
mation should be utilized in the design of
dosing schedules used in screening studies.
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Finally, there is a need for development of
animal screening methods that evaluate social
and emotional functioning and a need for
incorporation of assessments of mental health
functioning into human studies. Conversely,
there is a need to determine the role of devel-
opmental insult in the etiology ofhuman psy-
chiatric disorders through research on these
populations. The reconceptualization of
schizophrenia as a neurodevelopmental disor-
der has occurred over the last decade because
of epidemiological studies addressing prenatal
and adolescent variables (89-94). Also,
insights into the etiology of autism have been
gained through evaluation of the consistency
between symptomatology and the disruption




It is important that laboratory studies model
real-world exposure characteristics as closely
as possible. To this end, information about
the phasic versus tonic nature of exposure
and the corresponding pharmacokinetic
characteristics of the agent must be taken
into account whenever possible as a means of
strengthening the design of screening studies.
When exposure characteristics provide an
appropriate model of the human exposure
scenario, responses to exposure can then be
measured with all of the recommendations
and caveats that have been a major focus of
this paper.
This posed question is more formidable
in the context of human epidemiological
studies. Outside of the laboratory environ-
ment, exposure assessment in epidemiologi-
cal studies is challenging because these
studies lack simplified quantification to
address issues related to age-based vulnerabil-
ity and this assessment is often precluded by
the large numbers of individuals necessary
to permit breakdown into multiple age
groups. Although power calculations can pro-
vide reasonable estimates of the numbers of
people necessary to get reliable results, esti-
mates are more accurate when preexisting
data are available to identify the end point(s)
of interest and the magnitude of the effect to
be reasonably expected. When the effect is
easy to measure or to quantify, this makes it
simpler to use the minimum number of par-
ticipants determined using the power calcula-
tions. Otherwise, larger sample sizes need to
be used to attempt to find less readily
detectable effects. Aside from difficulties
inherent in satisfying sample size needs, how-
ever, there are greater complications associ-
ated with estimating exposure and measuring
the outcome of interest. Although estimating
exposure based on careful interview tech-
niques along with determinations of local
residual environmental contamination and
residues in human tissues is possible but
problematic, it has been more problematic to
associate exposures with narrow developmen-
tal time periods. Nevertheless, this may be
necessary to optimally estimate risks that are
highly stage dependent. When the environ-
mental or occupational contamination is
confined to a particular time period, studies
could attempt to parse the exposed partici-
pants into groups differing according to bio-
logically meaningful periods of exposure.
Provided that adequate sample sizes could be
used, selection of groups according to ongo-
ing developmental events at the time of
exposure might improve the ability to
address exposure-response events. In other
words, detectability might be optimized
under conditions where the biological plausi-
bility of the cause-effect relationship under
study is maximized by narrowing the win-
dow of exposure to the most vulnerable stage
of development. When groups include par-
ticipants exposed outside of the period of
greatest vulnerability for disruption of the
end point of interest, the presence of these
added participants could dilute the ability to
detect the effect. Thus, a trade-off between
sample size and sensitivity of the design is
always present and must be carefully consid-
ered. This issue is of paramount importance
in studies where major malformations are the
end points of interest.
It is also critical that the outcome of interest
be examined with attention to a number of
potential moderating variables. It is impor-
tant to design studies that address the interac-
tive effects of variables that may affect the
results, such as socioeconomic status, parental
smoking, alcohol, or illicit drug use, as well as
use of prescription or over-the-counter com-
pounds. Human lead studies [reviewed by
Dietrich et al. (38)] have paid a great deal of
attention to these variables, as have some
human studies of substances of abuse
[reviewed by Rice and Barone (18) and
Richardson and Day (95)].
Launching new large-scale, prospective,
longitudinal studies of diverse groups of chil-
dren and pregnant women would provide
sound information from which the effects of
various exposures on sensory, motor, cogni-
tive, emotional, and mental health outcomes
could be measured. Regular blood or tissue
sampling from the participants could provide
a database from which numerous questions
could be asked about developmental expo-
sures to specific agents. Such an ambitious
undertaking, however, would be quite costly
and lengthy. Nevertheless, the greatest benefit
would be derived from a prospective compre-
hensive design.
The limitations of retrospective designs
generally compromise the quality of the
information obtained. Nevertheless, a very
useful initial approach to addressing many
questions about developmental toxicity
involves the use of existing databases. Many
very large studies, such as the Collaborative
Perinatal Project (96) (a prospective longitu-
dinal study) and the National Health and
Nutrition Examination Study (NHANES)
(90) (a cross-sectional study), have been con-
ducted. NHANES periodically surveys a
sample of the U.S. population to assess a
large number of health parameters and bio-
logical measures. Thus, a database of ques-
tionnaire responses and a large collection of
stored serum, urine, and other specimens
exist for this population. NHANES IV is
currently in the data collection phase, and
should provide the greatest range to date of
specimens from the entire U.S. population.
These stored banks of biological specimens
could serve as valuable resources for investi-
gators who are not able to launch a com-
pletely new study. With respect to behavioral
outcomes, however, they are somewhat
limited and would no doubt demand addi-
tional data collection. Of particular value to
neurodevelopmental toxicity studies are
Scandinavian databases (90) that contain
extensive health records, extensive educa-
tional records, and scores on measures of
intellectual functioning.
Other Exposures May Interact
with Exposures of Concern
In human populations, the prevalence of
caffeine, cigarette, and alcohol use complicate
the study of specific toxic agents in the envi-
ronment. Similarly, diets of varying nutri-
tional quality and the use of commonly
prescribed psychoactive drugs or hormones
may interact with the assessment of risks of
exposure to environmental agents. Therefore,
it is important to determine the usage of
common substances when human experimen-
tal or epidemiological studies are done. In
studies of developmental neurotoxicity, the
influence of many of these variables on the
effects of nonelective exposures has been
addressed through statistical means:
Information is generally obtained via ques-
tionnaire and used as a covariate. Excellent
examples and descriptions of these
approaches can be found in reviews by
Bellinger and Dietrich (37), Dietrich et al.




Many conferences, symposia, and individual
publications have addressed the issues sur-
rounding the predictive value of rat and pri-
mate studies to humans. Of particular interest
has been how well animal behavioral data
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predict human behavioral responses. Efforts
to address this question have generally chosen
specific agents and categories of end points,
then looked for concordance in the demon-
stration of effects within each category. When
focusing on the extrapolation of animal
behavioral data, evaluations have been made
of the effects of specific neurotoxicants on
functional categories such as general develop-
mental landmarks, sensory, motor, learning
and memory, and social behavior (98,99).
This approach suggests that reliable and valid
animal data predict human responses very
well. For example, agents that disrupt
sensory-evoked potentials and other electro-
physiological parameters in humans produce
similar disruptions in rats and primates
(18,100). Further, behavioral dysfunctions
tend to depend on similar neural substrates
across species. Thus, the specific behavior dis-
rupted in one species can be linked to alter-
ations in particular neurobiological substrates
that also mediate a similar category of behav-
ior in humans (18,21).
Nevertheless, within the context of meth-
ods used in screening batteries, extrapolation
appears strongest with regard to effects on
sensory and motor functioning, and is some-
what less strong for cognitive or social func-
tioning. We emphasized the need to further
challenge the integrity of learning mecha-
nisms through task complexity as a means of
improving screening-level detection of
deficits in learning and memory. Whereas
models of social behaviors such as infant
suckling, maternal-infant interactions, or
reproductive behavior appear to produce
concordant effects across species, more com-
plex aspects of human social behavior have
not been modeled in animal studies of devel-
opmental toxicity. Likewise, approaches to
assessing animal behavioral end points that
adequately screen for potential effects on
emotional or mental health end points have
not been broadly applied. As the neuro-
biological understanding of mental health
disorders has expanded, it has become clear
that altered brain development may predis-
pose individuals to increased vulnerability to
stress and mental health disorders (89,90).
More attention to this research issue is
needed in both animal and human develop-
mental toxicity studies.
Implications for Risk
Assessment and Public Health
We emphasized certain shortcomings of
current screening approaches and epidemio-
logical studies, certain methodologies that
appear to be more sensitive in identification
of developmental neurotoxicity, and the need
for improved understanding of toxicity dur-
ing certain vulnerable periods or on certain
end points. Some of our discussion can be
translated into immediate actions, whereas
other points emphasize longer term goals that
demand more research and data before appli-
cation. Explicitly, we suggest the following:
* In rodent screening studies, when back-
ground data are not available on the
agent, allow a broad exposure window
from fertilization through adolescence for
agents that would have an extended expo-
sure period in humans.
* Use pharmacokinetic data and human
exposure characteristics to determine the
logical window of exposure for use during
screening studies aimed at risk assessment.
* When plausible and logical given the real-
world exposure situation, interweave mor-
phological and functional testing into
multigenerational studies to cover the full
spectrum of development (i.e., womb
to tomb).
* Determine the nature of developmental
neurotoxicity following exposures before
the induction of the neural plate and dur-
ing the adolescent period.
* Use more contemporary and sensitive
methodologies for evaluating behavior
when the methodologies are amenable to
the screening context-add prepulse inhi-
bition to the startle paradigm, improve
water maze learning tasks by the addition
of reversal learning, and examine morpho-
logical and functional effects in young as
well as aged animals.
* Develop measures of cumulative learning
that are amenable to the screening context
and determine if these are more sensitive
than the basic learning tasks currently
used.
* Increase the use of neuropathological
assessments to cover the broader spectrum
of development of the brain. This could
be performed in screening studies with
the examination of the brain in both tera-
tology and multigenerational study proto-
cols. It could also complement other work
performed in developmental neurotoxicity
screening studies.
* Develop screening techniques that exam-
ine cytoarchitectural and molecular
aspects of nervous system functioning.
* Examine the relationship between
sensitive measures of neuroanatomy,
molecular functioning, and behavioral
compromise (with the long-term goal of a
viable tiered approach to the selection of
agents for behavioral evaluation based on
altered neural structure or molecular
characteristics).
* Use biological plausibility for causation of
the outcome of interest to narrow the
developmental periods now examined in
epidemiological studies.
* Perform preliminary examinations of
developmental neurotoxicity in humans
and seek concurrent validation of results
through the examination of data derived
from larger samples available in existing
databases.
* Initiate human prospective and longitudi-
nal studies that collect tissue samples as
well as neuropsychological data.
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